INAB IN8bio, Inc: Rasio Kapitalisasi Pasar marang Nilai Buku

The current price-to-book ratio of IN8bio, Inc. (INAB) reflects asset dynamics where 0.51 serves as the base parameter value. Investors face uncertainty due to the complexity of live cell production and the high cost of development. Meanwhile, IN8bio, Inc. (INAB) is recognized as an authority in creating bone marrow-sparing gamma-delta therapy. Currently, the company's scientific potential is focused on the intensive study of methods to combat glioblastoma.

IN8bio, Inc. (INAB) - Rasio Kapitalisasi Pasar marang Nilai Buku saka 04.07.2022 nganti 28.10.2026

INAB (IN8bio Inc.): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Rega saham IN8bio, Inc.|INAB - Bagan rega target

- data kapitalisasi pasar:

Kapitalisasi pasar IN8bio, Inc|INAB - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Buku saben Saham IN8bio|INAB - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku in8bio.com|INAB - Total Aset Bisnis

- data utang lan likuiditas:

Total Utang marang Modal IN8bio, Inc.|INAB - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal IN8bio, Inc|INAB - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku IN8bio, Inc

Pambiji fundamental:INAB (IN8bio, Inc.)

This ratio reflects the market premium over net assets, determining the efficiency of equity capitalization. By analyzing the market cap to book value trend, an investor assesses the justification of market value relative to the balance sheet. For IN8bio, Inc. (INAB), a high valuation is supported by the implementation of industrial robotic blood analysis systems. Laboratory automation creates the foundation for scaling the business, which minimizes the risks of a sharp devaluation of shares.

Pesaing utama